Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...

The FDA has approved Jemperli plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.

Keytruda was also studied in people with advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) endometrial cancer who had received previous treatment for their cancer.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.

Jemperli's earlier indications across endometrial cancer and dMMR solid tumours have generated modest revenues, coming in at £36 million ($46 million) in the first six months of this year and ...

GSK plans to ask FDA for an accelerated approval of Jemperli as a neoadjuvant treatment for dMMR/MSI-H rectal cancer based on 12-month clinical complete response data from 130 patients across two ...